Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
mskcc score
—risk factors
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Good Risk0–0
  • Intermediate Risk1–2
  • High Risk3–5
Direct Clinical Answer

The Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC) calculator is designed for bedside predicting survival based on clinical and laboratory data in metastatic RCC patients in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic antineoplastic regimens.

Clinical Guidelines & Evidence

Predicts survival based on clinical and laboratory data in metastatic RCC patients

Clinical Indication

The Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC) is indicated for bedside clinical practice to support Predicts survival based on clinical and laboratory data in metastatic RCC patients. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.

Formula & Variables:

Score = Sum of present risk factors (0-5)

Input Parameters

NameTypeRequiredDescription
time_to_treatment_less_than_1_yearstringYesTime from initial diagnosis to systemic treatment < 1 year
hemoglobin_lowstringYesHemoglobin < lower limit of normal (Men: <13.5 g/dL, Women: <12.0 g/dL)
calcium_highstringYesCorrected calcium > 10 mg/dL (>2.5 mmol/L)
ldh_highstringYesLDH > 1.5x upper limit of normal (Normal ULN: 140 U/L, so >210 U/L)
performance_status_lowstringYesKarnofsky Performance Status < 80%

Score Interpretation & Guidance

RangeStageDescription
0–0Good Risk0 risk factors
1–2Intermediate Risk1-2 risk factors
3–5High Risk≥3 risk factors

Evidence-Based References (EBM)

  • Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40. doi: 10.1200/JCO.1999.17.8.2530.DOI: 10.1200/JCO.1999.17.8.2530
  • Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 Jan 1;20(1):289-96. doi: 10.1200/JCO.2002.20.1.289.DOI: 10.1200/JCO.2002.20.1.289
  • Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004 Feb 1;22(3):454-63. doi: 10.1200/JCO.2004.06.132.DOI: 10.1200/JCO.2004.06.132

Related calculators